Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

Flag­ship is build­ing a big-name C-suite at its new, $220 mil­lion merged biotech.

Reper­toire Im­mune Med­i­cines, which al­ready boasts for­mer Biover­a­tiv chief John Cox as its CEO, an­nounced yes­ter­day that An­tho­ny Coyle, the for­mer Pfiz­er CSO and the found­ing CEO of Pan­dion, will join as their head of R&D.

“As we progress clin­i­cal tri­als for our mul­ti-clon­al T cell can­di­dates in im­muno-on­col­o­gy, Tony’s deep ex­per­tise in cel­lu­lar im­munol­o­gy and nov­el ther­a­peu­tic de­vel­op­ment will help us achieve our vi­sion of cre­at­ing a new class of trans­for­ma­tive med­i­cines for pa­tients,” Cox said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER